SCOTTSDALE, Ariz., Nov. 11 /PRNewswire-FirstCall/ -- Motion DNA Corporation announced today its intent to expand its sales and marketing nationally and internationally through a group of independent distributors.
Motion DNA has worked over the last two years to revamp its software to a more user friendly version. With the final version nearing completion and ready for distribution, according to Zig Ziegler, CEO, "We have to add a minimum of 60 independent distributors just to support the influx of telephone calls which are now coming in. Each distributor will be assigned a specific state or regional area to promote the use of the Company's products to physical therapists, chiropractors, sports teams, and corporations interested in participating in the next frontier in sports medicine."
Distributors will be supplied with leads from the Company, but they also will be expected to conduct prospecting in their territories. The ideal candidate to purchase Motion DNA's technology has been expanded to include physical therapists, chiropractors, sports training facilities and even health clubs. Motion DNA's newest software can be used to evaluate sports motions and as a dynamic Goniometer for evaluating patients before and after beginning a rehabilitation program. The BioCap and Bio Trainer also include features which, when used while performing an exercise, can immediately warn a patient of the improper completion of a task.
With over 500,000 registered sports medicine professionals, health clubs, and over 30 million athletes in the US alone the company expects distributors to help get Motion DNA systems into the market. To support distributor efforts, the company has budgeted $2 million for marketing in 2006.
A distributor training conference is scheduled for December 16-18, 2005 in Scottsdale. Interested individuals or companies should submit a letter of interest outlining their experience to email@example.com.
Distributors will be asked to meet monthly and quarterly sales objectives for Motion DNA's BioCap and BioTrainer Systems. Distributors who meet their goals can expect to generate a minimum of $150,000 in gross revenue monthly. The Company will offer a special incentive program with the launch of its product sales next month.
This press release is available on the Motion DNA Corp. IR HUB for investor commentary, feedback and questions. Investors are asked to visit http://www.AGORAcom.com/IR/MotionDNA . Alternatively, investors are asked to e-mail all questions and correspondence to MTDX@agoracom.com where they can request to be placed on the investor E-mail list to receive all future press releases and correspondence on a timely basis.
About Motion DNA:
Motion DNA Corporation develops products for diagnostic testing for medical professionals and sports organizations. Motion DNA's biomechanical analyses and detailed reports provide its customers and consumers with solutions for preventing injuries, identifying physical limitations, diagnosing preexisting injuries related to biomechanics, and improving physical performance levels. The company's technology will be available for sale beginning in December of 2005. For additional information on the company, please visit the company website at www.motiondnacorp.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.
Corporate Inquiries Curt Blakeney, Director of Public Relations
AGORA Investor Relations
Motion DNA Corporation